Proteomics International FY2026 Annual Report

FY2026 was a year of transition and reset. The Company advanced its Promarker^® portfolio, strengthened clinical and laboratory capability, expanded clinical evidence, and refined its commercial approach for the next stage of growth.

Proteomics International enters FY2027 focused on translating its proteomics platform into clinically adopted diagnostics, sustainable commercial pathways, and long-term shareholder value.

FY2026 was a year in which the Company moved from product development and initial market access activity toward a more disciplined commercial execution model.

The Company progressed its diagnostic portfolio, strengthened its laboratory and quality systems, expanded evidence generation, reinforced its intellectual property portfolio, and refined its commercial priorities.

Following a strategic and operational review, the Company suspended its direct-to-consumer (DTC) strategy, commenced the OxiDx strategic review, and completed an organisational restructure. The Company is now focused on targeted clinical adoption, controlled market introductions, distribution partnerships, laboratory readiness, and disciplined capital allocation.

Proteomics International remains focused on improving patient outcomes through earlier and more precise diagnostics, while building a sustainable business capable of creating long-term shareholder value.

View ASX Announcement: here

View Annual Report online: here

Download Annual Report: here